Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives $58.20 Average Price Target from Analysts

Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) have been given a consensus recommendation of "Buy" by the eleven ratings firms that are currently covering the stock, Marketbeat reports. Ten analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $58.20.

MIRM has been the topic of several research reports. Robert W. Baird increased their price target on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an "outperform" rating in a research report on Thursday, February 27th. HC Wainwright raised their price target on Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a "buy" rating in a research report on Friday, February 28th.

Insider Activity at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, COO Peter Radovich sold 2,627 shares of Mirum Pharmaceuticals stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $48.22, for a total value of $126,673.94. Following the completion of the sale, the chief operating officer now owns 26,961 shares in the company, valued at $1,300,059.42. The trade was a 8.88 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Jolanda Howe sold 750 shares of the stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total transaction of $32,115.00. Following the transaction, the senior vice president now owns 2,926 shares in the company, valued at approximately $125,291.32. The trade was a 20.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 133,679 shares of company stock worth $6,007,081. 22.87% of the stock is currently owned by insiders.

Remove Ads

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in MIRM. Jones Financial Companies Lllp grew its position in Mirum Pharmaceuticals by 100.0% during the fourth quarter. Jones Financial Companies Lllp now owns 714 shares of the company's stock valued at $30,000 after acquiring an additional 357 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Mirum Pharmaceuticals during the 4th quarter worth about $35,000. GF Fund Management CO. LTD. acquired a new stake in Mirum Pharmaceuticals during the 4th quarter worth approximately $42,000. R Squared Ltd acquired a new stake in Mirum Pharmaceuticals during the 4th quarter worth approximately $69,000. Finally, AlphaQuest LLC raised its holdings in Mirum Pharmaceuticals by 969.6% in the fourth quarter. AlphaQuest LLC now owns 1,829 shares of the company's stock valued at $76,000 after buying an additional 1,658 shares during the period.

Mirum Pharmaceuticals Price Performance

MIRM traded down $0.09 during trading on Tuesday, reaching $45.99. 155,893 shares of the stock were exchanged, compared to its average volume of 520,782. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. The company has a market capitalization of $2.25 billion, a price-to-earnings ratio of -22.77 and a beta of 1.04. Mirum Pharmaceuticals has a 1 year low of $23.14 and a 1 year high of $54.23. The business's 50 day moving average price is $48.01 and its two-hundred day moving average price is $43.86.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.22). Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The business had revenue of $99.41 million during the quarter, compared to analysts' expectations of $96.64 million. As a group, equities research analysts anticipate that Mirum Pharmaceuticals will post -1.43 earnings per share for the current year.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.